325 related articles for article (PubMed ID: 25055137)
21. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
Yamada S; Ishida Y; Matsuno A; Yamazaki K
Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427
[TBL] [Abstract][Full Text] [Related]
22. FOXP1 molecular cytogenetics and protein expression analyses in primary cutaneous large B cell lymphoma, leg-type.
Espinet B; García-Herrera A; Gallardo F; Baró C; Salgado R; Servitje O; Estrach T; Colomo L; Romagosa V; Barranco C; Serrano S; Campo E; Pujol RM; Solé F
Histol Histopathol; 2011 Feb; 26(2):213-21. PubMed ID: 21154235
[TBL] [Abstract][Full Text] [Related]
23. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
[TBL] [Abstract][Full Text] [Related]
24. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.
Oishi N; Kondo T; Nakazawa T; Mochizuki K; Tanioka F; Oyama T; Yamamoto T; Iizuka J; Tanabe K; Shibata N; Kirito K; Katoh R
Pathol Int; 2015 Oct; 65(10):528-35. PubMed ID: 26388135
[TBL] [Abstract][Full Text] [Related]
25. Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.
Ducharme O; Beylot-Barry M; Pham-Ledard A; Bohers E; Viailly PJ; Bandres T; Faur N; Frison E; Vergier B; Jardin F; Merlio JP; Gros A
J Invest Dermatol; 2019 Nov; 139(11):2334-2342.e8. PubMed ID: 31150604
[TBL] [Abstract][Full Text] [Related]
26. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
Cao XX; Li J; Cai H; Zhang W; Duan MH; Zhou DB
Ann Hematol; 2017 Nov; 96(11):1867-1871. PubMed ID: 28803429
[TBL] [Abstract][Full Text] [Related]
27. Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia.
Insuasti-Beltran G; Gale JM; Wilson CS; Foucar K; Czuchlewski DR
Arch Pathol Lab Med; 2015 Aug; 139(8):1035-41. PubMed ID: 26230596
[TBL] [Abstract][Full Text] [Related]
28. Allele-specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples.
Staiger AM; Ott MM; Parmentier S; Rosenwald A; Ott G; Horn H; Griese EU
Br J Haematol; 2015 Oct; 171(1):145-8. PubMed ID: 25816840
[No Abstract] [Full Text] [Related]
29. Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma.
Pham-Ledard A; Prochazkova-Carlotti M; Andrique L; Cappellen D; Vergier B; Martinez F; Grange F; Petrella T; Beylot-Barry M; Merlio JP
Mod Pathol; 2014 Mar; 27(3):402-11. PubMed ID: 24030746
[TBL] [Abstract][Full Text] [Related]
30. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
Abeykoon JP; Paludo J; King RL; Ansell SM; Gertz MA; LaPlant BR; Halvorson AE; Gonsalves WI; Dingli D; Fang H; Rajkumar SV; Lacy MQ; He R; Kourelis T; Reeder CB; Novak AJ; McPhail ED; Viswanatha DS; Witzig TE; Go RS; Habermann TM; Buadi FK; Dispenzieri A; Leung N; Lin Y; Thompson CA; Hayman SR; Kyle RA; Kumar SK; Kapoor P
Am J Hematol; 2018 Feb; 93(2):187-194. PubMed ID: 29080258
[TBL] [Abstract][Full Text] [Related]
31. The histomorphologic spectrum of primary cutaneous diffuse large B-cell lymphoma: a study of 79 cases.
Plaza JA; Kacerovska D; Stockman DL; Buonaccorsi JN; Baillargeon P; Suster S; Kazakov DV
Am J Dermatopathol; 2011 Oct; 33(7):649-55; quiz 656-8. PubMed ID: 21937906
[TBL] [Abstract][Full Text] [Related]
32. Atypical clinicopathologic presentation of primary cutaneous diffuse large B-cell lymphoma, leg type.
Massone C; Fink-Puches R; Wolf I; Zalaudek I; Cerroni L
J Am Acad Dermatol; 2015 Jun; 72(6):1016-20. PubMed ID: 25824272
[TBL] [Abstract][Full Text] [Related]
33. MYD88
Qin Y; Qiu T; Xie Z; Chen X; Liu P; Yang J; He X; Gui L; Zhou S; Jiang H; Zhang C; Yang S; Tang L; Shi Y
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8483-8494. PubMed ID: 37093346
[TBL] [Abstract][Full Text] [Related]
34. MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma.
Martinez-Lopez A; Curiel-Olmo S; Mollejo M; Cereceda L; Martinez N; Montes-Moreno S; Almaraz C; Revert JB; Piris MA
Am J Surg Pathol; 2015 May; 39(5):644-51. PubMed ID: 25723115
[TBL] [Abstract][Full Text] [Related]
35. Development of high-resolution melting analysis for the detection of the MYD88 L265P mutation.
Wang CZ; Lin J; Qian J; Shao R; Xue D; Qian W; Xiao GF; Deng ZQ; Yang J; Li Y; Chen XX
Clin Biochem; 2013 Mar; 46(4-5):385-7. PubMed ID: 23178471
[TBL] [Abstract][Full Text] [Related]
36. Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification.
Senff NJ; Hoefnagel JJ; Neelis KJ; Vermeer MH; Noordijk EM; Willemze R;
Arch Dermatol; 2007 Dec; 143(12):1520-6. PubMed ID: 18087001
[TBL] [Abstract][Full Text] [Related]
37. Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.
Fox LC; Yannakou CK; Ryland G; Lade S; Dickinson M; Campbell BA; Prince HM
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29899297
[TBL] [Abstract][Full Text] [Related]
38. The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma.
Elbaz O; Shaat RM; Abd El Ghaffar HA; Shamaa S; Abdel-Masseih HM; Anber N; Mortada MI
Asian Pac J Cancer Prev; 2023 Jul; 24(7):2485-2491. PubMed ID: 37505783
[TBL] [Abstract][Full Text] [Related]
39. MYD88 L265P mutation promoted malignant B cell resistance against T cell-mediated cytotoxicity via upregulating the IL-10/STAT3 cascade.
Qiu H; Gong S; Xu L; Cheng H; Gao L; Chen J; Hu X; Yang J
Int Immunopharmacol; 2018 Nov; 64():394-400. PubMed ID: 30253331
[TBL] [Abstract][Full Text] [Related]
40. MyD-88 L265P mutations are present in some cases of vitreoretinal lymphoma.
Pulido JS; Salomao DR; Frederick LA; Viswanatha DS
Retina; 2015 Apr; 35(4):624-7. PubMed ID: 25768255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
